Pfizer Inc (PFE) — closed signal from April 24, 2026
Partial Published before the outcome was known, scored automatically when the window closed on July 23, 2026.
Predicted vs. what happened
PFE price · publication thesis → realized outcomesplit-adjusted
$24.12 – $25.05Entry zone — fair-value band
$25.81Published — price the day we called it
$26.70Target — the price the thesis aimed for
$26.67Peak — highest point inside the window, not a realized return
$24.58Window close — end-of-window price, context only
What happened
Partial
Reached 47% of the predicted growth at its peak, without hitting the target.
Peak price
$26.67
peak on April 28, 2026 — not a realized returnPeak gain
+3.3%
peak, from the publication priceWindow close
$24.58
end-of-window price, context onlyDays to target
—
Window
April 24, 2026 – July 23, 2026
The thesis — published April 24, 2026
Predicted growth
+7%
over the measurement windowTarget price
$26.70
the price the thesis aimed forEntry zone
$24.12 – $25.05
the fair-value band we waited forPrice at publication
$25.81
published April 24, 2026Confidence
63%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Pfizer looks like a beaten-down healthcare name that could bounce if investors favor safer stocks, but the near-term story is weak. Most recent developments apply to the whole industry, not Pfizer specifically, and competitors have stronger progress in obesity drugs, so the path to a clear recovery is limited for now.
Primary drivers
- Shares fell enough to allow a short-term stabilization bounce
- Defensive healthcare often draws interest when markets wobble
- Consistent earnings wins give some support to sentiment
- Industry headlines are active, company-specific news is sparse
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.